Comparison · NCT03007394-2997cfd9
Lorcaserin vs Placebo Oral Capsule: The Secondary Endpoint is the Actual Number of Subjects That Successfully Achieve Abstinence From Cocaine During the Last Three Weeks of Treatment Who Are Either Non-Drinkers or Who Are Attempting Alcohol Abstinence
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Lorcaserin vs Placebo Oral Capsule: The Secondary Endpoint is the Actual Number of Subjects That Successfully Achieve Abstinence From Cocaine During the Last Three Weeks of Treatment Who Are Either Non-Drinkers or Who Are Attempting Alcohol Abstinence. Trial comparisons, record NCT03007394-2997cfd9. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT03007394-2997cfd9
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0 | 0 | 0.0315 | wilson | |
| Risk in group 2 | 0.0242 | 0.00826 | 0.0687 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0242 | -0.0687 | 0.0111 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | log | a group has no participants with the outcome | |||
| Odds ratio, group 1 over group 2 | log | a cell of the two-by-two table is zero | |||
| Number needed to treat, for one fewer participant with the outcome on Lorcaserin than on Placebo Oral Capsule | 41.3 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Lorcaserin | 10 mg capsule by mouth, twice a day, for 13 weeks~Lorcaserin: Lorcaserin Capsule | 0 | 118 | OG000 |
| Group 2 | Placebo Oral Capsule | 10 mg placebo capsule, twice a day, for 13 weeks~Placebo Oral Capsule: sugar pill to mimic lorcaserin 10mg capsule | 3 | 124 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
The Secondary Endpoint is the Actual Number of Subjects That Successfully Achieve Abstinence From Cocaine During the Last Three Weeks of Treatment Who Are Either Non-Drinkers or Who Are Attempting Alcohol Abstinence
- Description
- Time frame
- Treatment weeks 11-13
- Population
Source ClinicalTrials.gov
Trial
- Title
- Lorcaserin in the Treatment of Cocaine Use Disorder
- NCT number
- NCT03007394
- Phases
- PHASE2
- Conditions
- Cocaine-Related Disorders
- Interventions
- Lorcaserin, Placebo Oral Capsule
- Lead sponsor
- National Institute on Drug Abuse (NIDA)
- Results first posted
- 2020-06-19
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT03007394?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT03007394-2997cfd9